About Allegro Diagnostics
Allegro Diagnostics is a Healthcare company based in Maynard (United States) founded in 2006, and was acquired by Veracyte in September 2014. Genomic tests for lung cancer using next-generation sequencing were developed. Allegro Diagnostics has raised $9.4 million across 4 funding rounds from investors including HHS, Veracyte and Boston University. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its competitors include Invitae, Genome Medical and Myriad Genetics; 2 of its 3 listed competitors have raised funding.
Company details
Allegro Diagnostics was founded in 2006 in Maynard, United States, within the genomics and diagnostics sector. Focus was placed on developing tests for lung cancer, including the flagship BronchoGen assay. Next-generation sequencing was employed to assess inconclusive lung nodules from bronchoscopies, determining if they were cancerous or benign. The company was acquired by Veracyte in September 2014 for 21 million.
- Headquarters Maynard, United States
- Stage Acquired
- SectorsHealthcare
- Website allegrodx.com
- Social LinkedIn
- Acquired by Veracyte (Sep 2014)
Funding Insights of Allegro Diagnostics
Allegro Diagnostics has successfully raised a total of $9.4M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.4 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.4M
- Total Rounds 4
- Last Round Series A — $5.4M
- First Round $4M
(Mar 2008)
- Investors Count 5
All 4 funding rounds of Allegro Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2011 | $5.4M | Series A | – | Kodiak Venture Partners, CHV | – |
| Oct 2009 | $2.8M | Grant | – | – | |
| Sep 2009 | $2.93M | Grant | – | – | |
| Mar 2008 | $4M | Series A | – | Kodiak Venture Partners |
6 investors in total: 6 institutional.
Investors in Allegro Diagnostics
Allegro Diagnostics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Veracyte and Boston University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early stage venture fund investing in North America and Canada | kodiakvp.com | Waltham, United States | ||
| chv.vc | ||||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Multiple courses and degrees are offered across diversified academic streams. | 1869 | bu.edu | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Genomics-based diagnostic tests for cancer are developed. | 2008 | veracyte.com | San Francisco, United States |
Investor details for Allegro Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Allegro Diagnostics
4 dated milestones of Allegro Diagnostics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Allegro Diagnostics is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series A, of $5.4M.
- Exit Acquired by Veracyte.
Competitors of Allegro Diagnostics
Allegro Diagnostics has 3 listed competitors in our database, 2 of them funded. They include Invitae, Genome Medical and Myriad Genetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| genomemedical.com | 2016 | Monterey, United States | $172.98M | 84 | Genomic testing services are provided clinically and directly to consumers. | |
| myriad.com | 1991 | United States | 2,700 | Molecular diagnostics and personalized medicine for cancer are developed. |
Detailed competitors of Allegro Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Allegro Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allegro Diagnostics
Complete news archive for Allegro Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allegro Diagnostics
Allegro Diagnostics was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Allegro Diagnostics is headquartered in Maynard, United States. It is registered at Maynard, Massachusetts, United States.
Allegro Diagnostics is a funded company, having raised a total of $9.4M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Mar 2008.
Allegro Diagnostics was founded in 2006 in Maynard, United States, within the genomics and diagnostics sector. Focus was placed on developing tests for lung cancer, including the flagship BronchoGen assay. Next-generation sequencing was employed to assess inconclusive lung nodules from bronchoscopies, determining if they were cancerous or benign. The company was acquired by Veracyte in September 2014 for 21 million.
Allegro Diagnostics's top competitors include Myriad Genetics, Genome Medical and Invitae.
Allegro Diagnostics has 6 investors. Key investors include HHS, Veracyte, Boston University, National Cancer Institute, and Kodiak Venture Partners.
Yes. Allegro Diagnostics was acquired by Veracyte in September 2014.